- CONSORT Evidence Database
- CONSORT Statement
- CONSORT Statement Extensions
- Evidence underpinning CONSORT
- Accrual and sample size
- Attitudes to trials
- Adverse events (Harms)
- Baseline data
- Early stopping
- Intention to treat
- Outcome reporting
- Random allocation
- Statistical analysis
- Statistical methods
- Trial design issues
- Trial registration
- Related guidelines and initiatives
- Useful sites
Chen W, Gluud C, Kjaergard LL. Association of funding
and conclusions in randomized drug trials: a reflection of treatment effect or
adverse events? JAMA 2003; 290(7):921-928.
Barden J, Derry S, Mcquay HJ, Moore RA. Bias from industry
trial funding? A framework, a suggested approach, and a negative result. Pain
Bekelman JE, Li Y, Gross CP. Scope and impact of financial
conflicts of interest in biomedical research: a systematic review. JAMA 2003;
Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated
with findings of published trials of drug-drug comparisons: why some statins
appear more efficacious than others. PLoS Med 2007; 4(6):e184.
Bero LA, Rennie D. Influences on the quality of published
drug studies. Int J Technol Assess Health Care 1996; 12(2):209-237.
Brown A, Kraft D, Schmitz SM, Sharpless V, Martin C, Shah
R, Shaheen NJ. Association of industry sponsorship to published outcomes in
gastrointestinal clinical research. Clin Gastroenterol Hepatol 2006; 4(12):1445-1451.
Chalmers I, Rounding C, Lock K. Descriptive survey of
non-commercial randomised controlled trials in the United Kingdom, 1980-2002.
BMJ 2003; 327(7422):1017.
Clifford TJ, Moher D, Barrowman N. Absence of associations between funding source, trial outcome, and quality score: a benefit of financial disclosure? 4th International Congress on Peer Review in Biomedical Publication, September 14 16, 2001 in Barcelona, Spain 2001.
Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, Kotzin S, Nicholls MG, Nylenna M, Overbeke AJ, Sox HC, Van Der Weyden MB, Wilkes MS. Sponsorship, authorship, and accountability. JAMA 2001; 286(10):1232-1234.
PMID: 11559271 [New]
DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: the adverse effects of industry influence. JAMA 2008; 299(15):1833-1835.
PMID: 18413880 [New]
Decullier E, Chapuis F. Impact of funding on biomedical
research: a retrospective cohort study. BMC Public Health 2006; 6:165.
Etter JF, Burri M, Stapleton J. The impact of
pharmaceutical company funding on results of randomized trials of nicotine
replacement therapy for smoking cessation: a meta-analysis. Addiction 2007;
Gøtzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman
DG, Chan AW. Constraints on publication rights in industry-initiated clinical
trials. JAMA 2006; 295(14):1645-1646.
Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews
compared with industry supported meta-analyses and other meta-analyses of the
same drugs: systematic review. BMJ 2006; 333(7572):782.
Kjaergard LL, Gluud C. Funding, disease area, and internal
validity of hepatobiliary randomized clinical trials. Am J Gastroenterol 2002; 97(11):2708-2713.
Lesser LI, Ebbeling CB, Goozner
M, Wypij D, Ludwig DS. Relationship between funding
source and conclusion among nutrition-related scientific articles. PLoS Med
Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical
industry sponsorship and research outcome and quality: systematic review. BMJ
Liss H. Publication bias in the pulmonary/allergy
literature: effect of pharmaceutical company sponsorship. Isr Med Assoc J 2006;
Melander H, hlqvist-Rastad J, Meijer G, Beermann B.
Evidence b(i)ased medicine--selective reporting from studies sponsored by
pharmaceutical industry: review of studies in new drug applications. BMJ 2003;
Moja PL, Moschetti I, D'Amico R. Outcome reporting bias in
government-funded RCTs. CMAJ 2005; 172(7):857.
Montgomery JH, Byerly M, Carmody T, Li B, Miller DR,
Varghese F, Holland R. An analysis of the effect of funding source in
randomized clinical trials of second generation antipsychotics for the
treatment of schizophrenia. Control Clin Trials 2004; 25(6):598-612.
Perlis RH, Perlis CS, Wu Y, Hwang
C, Joseph M, Nierenberg AA. Industry sponsorship and
financial conflict of interest in the reporting of clinical trials in
psychiatry. Am J Psychiatry 2005; 162(10):1957-1960.
Ridker PM, Torres J. Reported outcomes in major
cardiovascular clinical trials funded by for-profit and not-for-profit
organizations: 2000-2005. JAMA 2006; 295(19):2270-2274.
Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008; 299(15):1800-1812.
PMID: 18413874 [New]
Safer DJ. Design and reporting modifications in
industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002;
Scharf O, Colevas AD. Adverse event reporting in
publications compared with sponsor database for cancer clinical trials. J Clin
Oncol 2006; 24(24):3933-3938.
Shah RV, Albert TJ, Bruegel-Sanchez V, Vaccaro AR,
Hilibrand AS, Grauer JN. Industry support and correlation to study outcome for
papers published in Spine. Spine 2005; 30(9):1099-1104.
Thomas O, Thabane L, Douketis J, Chu R, Westfall AO, Allison DB. Industry funding and the reporting quality of large long-term weight loss trials. Int J Obes (Lond) 2008;
PMID: 18711388 [New]
Tuech JJ, Moutel G, Pessaux P, Thoma V, Schraub S, Herve C.
Disclosure of competing financial interests and role of sponsors in phase III
cancer trials. Eur J Cancer 2005; 41(15):2237-2240.
Tulikangas PK, Ayers A, O'Sullivan DM. A meta-analysis
comparing trials of antimuscarinic medications funded by industry or not. BJU
Int 2006; 98(2):377-380.
Wahlbeck K, Adams C. Beyond conflict of interest. Sponsored
drug trials show more-favourable outcomes. BMJ 1999; 318(7181):465.
Yaphe J, Edman R, Knishkowy B, Herman J. The association
between funding by commercial interests and study outcome in randomized
controlled drug trials. Fam Pract 2001; 18(6):565-568.
Page last edited: 06 May 2009